|
|
Article: Research conducted at Q.P. Liao and co-authors has provided new information about female sexual arousal disorder.(Report)
- Article from:
- Women's Health Weekly
- Article date:
- September 4, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
In this recent report, researchers in Beijing, People's Republic of China conducted a study "To date, no approved medication is available for the treatment of female sexual arousal disorder (FSAD). The purpose of this study was to evaluate the clinical efficacy and safety of a novel alprostadil topical cream for the treatment of FSAD."
"This was a multicenter, randomized, double blind, placebo-controlled, parallel design dose-ranging study. Four hundred female patients with FSAD (22-62 years of age), after a 4-week nontreatment baseline period, were provided with 10 blinded doses of 500, 700, or 900 mcg alprostadil or a placebo cream to be applied to the ...